Update: Amgen Facing US Antitrust Lawsuit Filed by Sandoz

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Update: Amgen Facing US Antitrust Lawsuit Filed by Sandoz

, MT Newswires - 10:13 AM ET 4/14/2025 default

10:13 AM EDT, 04/14/2025 (MT Newswires) -- (Updates with statement from Amgen's ( AMGN ) spokesperson in the fifth paragraph.)

Amgen ( AMGN ) is facing an antitrust lawsuit in the US filed by Sandoz, accusing Amgen ( AMGN ) of "extending and entrenching" the leading market position of its Enbrel medicine, also known as etanercept.

Sandoz said Monday that Amgen ( AMGN ) "blocked competition" from Enbrel biosimilars, including Erelzi from Sandoz, by illegally acquiring and using certain patent rights to entrench its market position.

Enbrel is approved in the US for patients with disabling inflammatory diseases and Sandoz said it received US FDA approval for Erelzi in 2016.

Apart from damages, Sandoz is seeking an injunction to prevent Amgen ( AMGN ) from using certain patent rights to block Enbrel's biosimilar competition and allow it to launch Erelzi, according to the statement.

"We do not comment on pending litigation," an Amgen ( AMGN ) spokesperson told MT Newswires in an email.

Price: 289.21, Change: +3.23, Percent Change: +1.13

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.